WHO study finds no benefit from remdesivir on COVID-19 deaths, hospital stays

The antiviral drug remdesivir had no substantial impact on the survival of COVID-19 patients or the length of their hospital stays, according to a World Health Organization (WHO) clinical trial.
Source: TEST FEED1

About Author

Connect with Me:

Leave a Reply

Your email address will not be published. Required fields are marked *

Rating*